Lead Product(s): NPT1220-312
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: ALS Association
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Funding February 17, 2020
The funding will support the preclinical evaluation and development of Neuropore's leading Toll-Like Receptor 2 (TLR2) antagonist NPT1220-312 for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): NPT520-34
Therapeutic Area: Healthy Volunteers Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2020
The Phase 1 study was designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of NPT520-34.